Search Results

HOPE Registry Compares Concept Medical’s MagicTouch Sirolimus DCB and POBA in CLTI

November 1, 2023—The HOPE registry is a single-center prospective registry of patients with chronic limb-threatening ischemia (CLTI).

Enrollment Commences in FUTURE BTK Trial of Concept Medical’s MagicTouch Sirolimus-Coated Balloon

August 27, 2020—Concept Medical Inc. announced the enrollment of the first patient in the randomized controlled FUTURE BTK trial of the company’s MagicTouch sirolimus-coated balloon for percutaneous transluminal angioplasty (PTA) versus standard balloon angioplasty in the treatment of below-the-knee (BTK) artery disease in patients with critical limb ischemia (CLI).

FDA Grants Breakthrough Device Designation for MagicTouch PTA Sirolimus-Coated Balloon to Treat BTK PAD

August 13, 2019—Concept Medical Inc. announced that it has been granted Breakthrough Device Designation (BDD) from the FDA for its MagicTouch percutaneous transluminal angioplasty (PTA) sirolimus-coated balloon (SCB) catheter for the treatment of peripheral artery disease (PAD) below the knee (BTK).

Concept Medical’s MAGICAL BTK IDE Trial Begins Enrollment

January 16, 2025—Concept Medical Inc., announced the enrollment of the first patient in the pivotal MAGICAL BTK randomized controlled trial, which is being conducted in the United States under an FDA-approved investigational device exemption (IDE).

FUTURE SFA Trial of Concept Medical’s MagicTouch Sirolimus-Coated Balloon Commences Enrollment

September 14, 2020—Concept Medical, Inc. announced the commencement of enrollment in the FUTURE SFA randomized, double-blind, placebo-controlled, multicenter trial.

Concept Medical’s MagicTouch PTA SCB Receives IDE Approval to Study Treatment of BTK Arterial Disease

February 13, 2023—Concept Medical Inc. announced that its MagicTouch percutaneous transluminal angioplasty (PTA) sirolimus-coated balloon (SCB) has received FDA investigational device exemption (IDE) approval for the treatment of below-the-knee (BTK) arterial disease.

Population-Based Analysis Shows Continued Decline in AAA Mortality

June 2, 2021—In a population-based analysis involving multiple countries, Png et al found that abdominal aortic aneurysm (AAA) mortality continued to decrease in association with reductions in smoking and hypertension.

Vascular Pioneer Edward B. Diethrich, MD, 1935–2017

February 28, 2017—Edward B. Diethrich, MD, a pioneer in noninvasive cardiovascular disease diagnosis and innovative surgical and minimally invasive treatments, succumbed to complications of a brain tumor on February 23 at the age of 81. Dr. Diethrich was an internationally esteemed cardiovascular surgeon, inventor, and philanthropist. He is survived by his wife of 61 years, Gloria, two children, and eight grandchildren. A celebration of his life will be planned in the near future. Details will be posted at drteddiethrich.com.